aHUS, Atypical Hemolytic Uremic Syndrome
Conditions
Keywords
Atypical Hemolytic Uremic Syndrome, Azotemia, Hemolytic-Uremic Syndrome, Hemolysis, Syndrome, Disease, Pathologic Processes, Uremia, Kidney Diseases, Urologic Diseases, Anemia, Hemolytic, Anemia, Hematologic Diseases, Thrombotic Microangiopathies, Thrombocytopenia, Blood Platelet Disorders
Brief summary
It is a multicenter observational non-comparative study of the efficacy and safety of long-term pathogenetic Elizaria® therapy in patients with atypical Hemolytic Uremic Syndrome
Detailed description
After screening, patients meeting all of the inclusion / non-inclusion criteria and vaccinated against meningococcal infections were treated by Elizaria®. The study is planned to include at least 50 patients receiving Elizaria® for the aHUS treatment. The study will consist of a screening period of up to 4 weeks, including, if necessary, immunization with meningococcal vaccine, a treatment period of 52 weeks. Medication will be prescribed in accordance with routine medical practice. Accordingly to minimize the risks and subjectivity of assessments the methods adopted in the routine practice of treating patients with aHUS will be used. Investigators enroll patients with aHUS diagnosis who have indications for pathogenetic therapy and who are receiving Elizaria® under the government program. Patients will receive medication in accordance with the established requirements of national standards and protocols for the treatment of patients with aHUS. The registration of the amount of the drug used will be carried out on the basis of information in the Patient Diaries, as well as primary documentation.
Interventions
DRUGElizaria®
Induction cycle: 900 mg (3 vials of 30 mL, 10 mg/mL) intravenous infusion for 30 minutes once a week for 4 weeks. Maintenance therapy: 1200 mg (4 vials of 30 mL, 10 mg/mL) intravenous infusion for 30 minutes in Week 5, followed by 1200 mg every 14 days.
Sponsors
AO GENERIUM
Study design
Observational model
OTHER
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
2 Months to No maximum
Inclusion criteria
1. Written informed consent to study participation. 2. Male and female patients aged 2 months and older with documented atypical hemolytic uremic syndrome (aHUS)diagnosis. 3. By the time of inclusion in the study, Elizaria® should be prescribed as a pathogenetic therapy for aHUS;
Exclusion criteria
1\. Intolerance to eculizumab, or other components of the drug.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Change in platelet count compared to the screening level | 52 week | Change in platelet count at 52 week after treatment with study drug compared to baseline at screening |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Proportion of patients with normalized platelet levels | 52 week | Proportion of patients with normal platelet count at 52 week after initiation of study drug treatment |
| Proportion of patients with no thrombotic microangiopathy (TMA) events | 52 week | The absence of TMA-related events is defined as the absence, for at least 12 weeks, of: 1) a decrease in platelet counts greater than 25% from baseline at screening; 2) plasma therapy; 3) hemodialysis. |
| Proportion of TMA-related interventions | 52 week | The proportion of TMA-related interventions is defined as (number of plasma therapy sessions + number of hemodialysis sessions) / number of patient days. |
| Proportion of patients with complete TMA response | 52 week | Complete TMA response is defined as the absence of abnormalities in LDH and platelet levels + improvement in renal function (decrease in creatinine levels by 25% or more compared to the baseline value on screening) when performed at least two consecutive tests within 8 weeks |
| Change in eGFR (ml / min. / 1.73m2) compared with the baseline level at screening; | 52 week | Change in eGFR (mL/min/1.73m2) at 52 week after initiation of study drug treatment from baseline at screening |
| Change in lactate dehydrogenase (LDH) levels from baseline at screening | 52 week | Change in LDH levels at 52 week after starting study drug treatment from baseline at screening |
| Proportion of patients with more then 1 stage-improvement in chronic kidney desease (CKD) compared to baseline at screening. | 52 week | Proportion of patients with \>=1 stage improvement in CKD at 52 week after initiation of study drug treatment compared with baseline at screening |
| Proportion of patients with an increase in hemoglobin level of more than 20 g / l compared to the baseline level at screening. | 52 week | Proportion of patients with an increase in hemoglobin level of more than 20 g/l at 52 week after the start of study drug treatment compared with baseline at screening |
| Dynamics of membrane attack complex (MAC) level compared to baseline at Visit 2 | 52 week | Changes in MAC levels at 52 week compared to baseline |
| The frequency and severity of adverse events (AEs) | 52 weeks | Frequency and severity of adverse events (AEs), including serious adverse events (SAEs) and AEs associated with study drug use |
| Proportion of patients with antidrug antibodies | 52 weeks | Proportion of patients with antidrug antibodies; titer of antidrug antibodies and their neutralizing activity |
| Proportion of patients with an improvement in glomerular filtration rate (eGFR) of 15 ml / min / 1.73m2 or more compared to the baseline level at screening. | 52 week | Proportion of patients with improvement in eGFR of 15 ml/min/1.73m2 or more at 52 week after treatment with study drug compared to baseline at screening |
Countries
Russia
Outcome results
None listed